Indications
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...